Tempest’s pivotal amezalpat conundrum
How does the micro-cap biotech now finance a 700-patient phase 3 study?
Tempest kicks up a storm as Morpheus strikes again
Tempest Therapeutics confirms an earlier success with its lead project, and this time investors respond.
